Introduction {#sec1-0300060518772227}
============

Endotracheal intubation increases the heart rate (HR) and blood pressure (BP) to augment sympathetic responses.^[@bibr1-0300060518772227]^ In general, fluctuations in vital signs during intubation do not pose a threat in normal, healthy patients. However, adjuvant medications for hemodynamic stability are mandatory to reduce morbidity and mortality rates in patients with recent myocardial infarction, coronary artery disease, and cerebrovascular disease.^[@bibr2-0300060518772227]^ Most anesthetics effectively attenuate this response. A previous study showed that various agents effectively modify hemodynamic changes.^[@bibr3-0300060518772227]^ Around the time of that study, remifentanil was a new opioid undergoing multicenter clinical trials. Remifentanil is rapidly metabolized by nonspecific esterases in plasma and tissue; therefore, its half-life is short and onset time is rapid, similar to alfentanil. Because of remifentanil's rapid onset and ability to offset opioids, it has recently become more commonly used as adjuvant anesthetic for tracheal intubation to attenuate hemodynamic responses.^[@bibr4-0300060518772227],[@bibr5-0300060518772227]^ The differential dose of rocuronium and the fixed dose of remifentanil are associated with the timing and conditions of intubation.^[@bibr5-0300060518772227]^

However, the effects of these various agents on neuromuscular blockade have not been fully elucidated. A few studies have shown the effects of adjuvants on neuromuscular blockade.^[@bibr6-0300060518772227][@bibr7-0300060518772227]--[@bibr8-0300060518772227]^ One study revealed the effects of fentanyl, remifentanil, and dexmedetomidine on neuromuscular blockade.^[@bibr6-0300060518772227]^

The present study was performed to determine the effect of remifentanil on the time to reach optimal neuromuscular blockade for tracheal intubation under monitoring with train-of-four (TOF) electromyography.

Patients and methods {#sec2-0300060518772227}
====================

Patients {#sec3-0300060518772227}
--------

This was a prospective randomized case control study. The Institutional Review Board of The Catholic University of Korea, Suwon, Republic of Korea approved the study protocol (VC 12MISI0141).

After obtaining written informed consent, we enrolled adult patients who were scheduled for elective surgery. Patients with a history of cardiac, pulmonary, renal, hepatic, cerebral, or neuromuscular disease; an allergy to propofol or opioids; chronic alcohol or drug abuse; a body mass index of \>30 kg/m^2^; or pregnancy were excluded from this study.

Anesthesia {#sec4-0300060518772227}
----------

Upon arrival in the operating room, we applied standard monitoring including pulse oximetry, electrocardiography, HR measurement, end-tidal carbon dioxide measurement, and noninvasive monitoring of arterial BP. Neuromuscular transmission was monitored by TOF electromyography in accordance with the guidelines for good clinical research practice.^[@bibr9-0300060518772227]^ Responses to stimulation of the ulnar nerve were measured at the first dorsal interosseous muscle as described below.

After baseline measurements, the patients were randomly categorized into one of three groups using a computer program. Patients in Group R 0.5 received remifentanil at 0.5 µg/kg/minute, those in Group R 1.0 received remifentanil at 1.0 µg/kg/minute, and those in Group S received saline. The study solution consisted of either 2 mg of remifentanil diluted in a total volume of 100 mL of 0.9% sodium chloride or only 100 mL of 0.9% sodium chloride. The patients and physicians were blinded to the randomization process.

In all patients, general anesthesia was induced with 40 mg of lidocaine to prevent propofol infusion pain followed by infusion of 2 mg/kg of propofol over 30 s. After loss of the eyelash reflex, 0.6 mg/kg of rocuronium bromide was administered, and a continuous infusion of remifentanil was started through a 20-gauge venous cannula on the forearm. The 95% effective dose of rocuronium is 0.3 mg/kg;^[@bibr10-0300060518772227]^ for the present study, we used twice this dose (0.6 mg/kg).

Protocol {#sec5-0300060518772227}
--------

Neuromuscular blockade was monitored on the opposite forearm with intravenous access. It was assessed by stimulation of the ulnar nerve and recording of acceleromyographic responses using transcutaneous Ag/AgCl electrodes with TOF-Watch SX (Organon Ltd., Dublin, Ireland). The baseline stabilization and calibration sequence were performed immediately after loss of the patient's eyelash reflex. The automatic calibration procedure started with a 50-mA current to supramaximal stimulation. After confirming the calibration, the stimulus was changed to a TOF pattern at 2 Hz every 10 s. We recorded the time required to reach a TOF ratio (TOFR) of 25% (T~25~) and TOF score of 0 (T~0~).

We estimated the differential mean BP (MBP) and HR using the following equation:

Differential MBP (HR) = Baseline MPB (HR) − T~0~ MBP (HR).

Statistical analyses {#sec6-0300060518772227}
--------------------

All data are presented as mean ± standard deviation. A previous study showed that the optimal intubation time is 136 ± 35 s.^[@bibr5-0300060518772227]^ Calculation of the sample size was based on preliminary data, α = 0.05, power of 80%, three groups, effect size = 0.40, and, if the present study results were statistically significant, F (2.63) = 3.14. G\*Power analysis showed that a sample size of 25 patients per group was needed. Paired and unpaired Student's t tests and one- and two-way repeated-measures analysis of variance (ANOVA) were used to compare measurements within groups. The statistical analysis and sample size determination were performed using PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA).

Results {#sec7-0300060518772227}
=======

After application of the inclusion criteria, 75 patients ranging in age from 18 to 60 years with an American Society of Anesthesiologists (ASA) physical status of I or II were enrolled. All patients completed the study protocol. Demographic data were similar among the three groups of patients ([Table 1](#table1-0300060518772227){ref-type="table"}). Sex, age, height, weight, and body mass index did not differ among the groups. Group R 0.5, Group R 1.0, and Group S comprised 25 patients each.

###### 

Demographic data in the three study groups

![](10.1177_0300060518772227-table1)

                       Group S         Group R 0.5      Group R 1.0     P value
  -------------------- --------------- ---------------- --------------- ---------
  Number of patients   25              25               25              
  Sex (male/female)    12/13           12/13            13/12           0.95
  Age (years)          43.24 ± 12.32   46.80 ± 10.53    41.76 ± 11.64   1.27
  Height (cm)          164.56 ± 6.66   164.32 ± 10.01   167.18 ± 9.46   0.45
  Weight (kg)          66.66 ± 10.61   64.43 ± 12.43    65.72 ± 10.97   0.24
  BMI (kg/m^2^)        24.54 ± 3.00    23.67 ± 2.55     23.47 ± 3.07)   0.97

Data are presented as mean ± standard deviation or *n* patients.

Group S, saline infusion group; Group R 0.5, remifentanil 0.5 µg/kg/minute infusion group; Group R 1.0, remifentanil 1.0 µg/kg/minute infusion group; F, female; M, male; BMI, body mass index.

Comparison of the mean onset time of neuromuscular block among the three groups revealed that the time to reach T~0~ and T~25~ was longer in Groups R 0.5 and R 1.0 than in Group S ([Table 2](#table2-0300060518772227){ref-type="table"}); one-way ANOVA showed a significant difference among the groups (*P* \< 0.001). In Group S, the time to reach T~0~ and T~25~ was 130.0 ± 6.4 and 96.5 ± 6.4 s, respectively. The onset time of TOF was significantly lower in Group S than in Groups R 0.5 and R 1.0 (*P* \< 0.001).

###### 

Onset times to reach TOFR of 25% and TOF of 0 in the three study groups

![](10.1177_0300060518772227-table2)

                 Group S (n = 25)   Group R 0.5 (n = 25)   Group R 1.0 (n = 25)   P value
  -------------- ------------------ ---------------------- ---------------------- ---------
  TOF 0 (s)      130.0 ± 6.4        142.6 ± 6.0\*          183.0 ± 11.6\*^ ,†^    \<0.001
  TOFR 25% (s)   96.5 ± 6.4         106.9 ± 7.2\*          147.2 ± 11.3\*^ ,†^    \<0.001

Data are presented as mean ± standard deviation.

TOF, train-of-four; TOFR, TOF ratio; Group S, saline infusion group; Group R 0.5, remifentanil 0.5 µg/kg/minute infusion group; Group R 1.0, remifentanil 1.0 µg/kg/minute infusion group.

( \**P* \< 0.05 vs. Group R 0.5, †*P* \< 0.05 vs. Group S.)

The changes in MBP and HR are shown in [Figures 1](#fig1-0300060518772227){ref-type="fig"} and [2](#fig2-0300060518772227){ref-type="fig"}. Two-way ANOVA revealed significant differences among the groups (*P* \< 0.05). The hemodynamic changes over time demonstrated significantly lower MBP and HR. MBP and HR were calculated with respect to their difference between baseline and T~0~. The mean values and standard deviations were also calculated. Comparison of these values revealed statistically significant differences (*P* \< 0.05) ([Table 3](#table3-0300060518772227){ref-type="table"}).

![Comparison of the heart rate among the saline infusion group (Group S), remifentanil 0.5 µg/kg/minute infusion group (Group R 0.5), and remifentanil 1.0 µg/kg/minute infusion group (Group R 1.0). HR, heart rate; Base, baseline; T25, train-of-four ratio 25%; T0, train-of-four 0. \**P* \< 0.05 vs. baseline in the same group using two-way repeated-measures analysis of variance.](10.1177_0300060518772227-fig1){#fig1-0300060518772227}

![Comparison of the mean blood pressure among the saline infusion group (Group S), remifentanil 0.5 µg/kg/minute infusion group (Group R 0.5), and remifentanil 1.0 µg/kg/minute infusion group (Group R 1.0). MBP, mean blood pressure; Base, baseline; T25, train-of-four ratio 25%; T0; train-of-four 0. \**P* \< 0.05 vs. baseline in the same group using two-way repeated-measures analysis of variance.](10.1177_0300060518772227-fig2){#fig2-0300060518772227}

###### 

Difference in MBP and HR between baseline and train-of-four of 0 among the three study groups

![](10.1177_0300060518772227-table3)

                     Group S (n = 25)   Group R 0.5 (n = 25)   Group R 1.0 (n = 25)   P value
  ------------------ ------------------ ---------------------- ---------------------- ---------
  Differential MBP   13.04 ± 9.22       22.44 ± 8.98\*         34.32 ± 12.78\*^ ,†^   \<0.05
  Differential HR    2.56 ± 8.42        14.84 ± 7.53\*         16.00 ± 6.06\*^ ,†^    \<0.05

Data are presented as mean ± standard deviation.

Group S, saline infusion group; Group R 0.5, remifentanil 0.5 µg/kg/minute infusion group; Group R 1.0, remifentanil 1.0 µg/kg/minute infusion group; MBP, mean blood pressure; HR, heart rate.

( \**P* \< 0.05 vs. Group R 0.5, †*P* \< 0.05 vs. Group S.)

The BP and HR markedly decreased during intubation in the groups with remifentanil infusion.

Discussion {#sec8-0300060518772227}
==========

The premise of this study is that continuous infusion of remifentanil influences the time to reach optimal neuromuscular blockade for tracheal intubation using rocuronium under TOF monitoring. The study results indicate that an increased remifentanil dose delays the onset time to reach optimal neuromuscular blockade.

Remifentanil has an ester bond that is quickly hydrolyzed in plasma and tissue; therefore, the onset time and duration of action of remifentanil are short.^[@bibr11-0300060518772227],[@bibr12-0300060518772227]^ Remifentanil is commonly used to maintain hemodynamic stability during tracheal intubation and is considered to provide an optimal pharmacological profile to treat the potentially adverse hemodynamic responses of tracheal intubation.^[@bibr13-0300060518772227]^ However, the adverse effects of remifentanil are similar to those of other opioids and include intense vagotonic and sympatholytic effects that result in bradycardia, hypotension, chest wall rigidity, nausea, and vomiting.^[@bibr12-0300060518772227],[@bibr14-0300060518772227]^ Several studies have shown that remifentanil causes cardiovascular compromise during induction, which in turn alleviates the sympathetic stimulation caused by endotracheal intubation.^[@bibr15-0300060518772227]^ These studies proved that remifentanil decreases the systemic circulation. Therefore, continuous infusion of remifentanil at different doses affects neuromuscular pharmacodynamics.

Rocuronium bromide is a widely used neuromuscular relaxant. Its onset and duration are affected by various inhalation anesthetics, local anesthetics, and adjuvant drugs such as esmolol and ephedrine.^[@bibr6-0300060518772227],[@bibr7-0300060518772227],[@bibr16-0300060518772227]^ The delayed onset time of rocuronium is probably due to decreased cardiac output, circulation time, and muscle perfusion. Kuipers et al.^[@bibr17-0300060518772227]^ reported that cardiac output influences rocuronium pharmacokinetics and pharmacodynamics.

When using remifentanil, cardiac output can decrease and the onset time of rocuronium can be affected. We can therefore assume that an increased remifentanil dose can delay the time to reach optimal blockade for intubation. The TOFR was used to determine the accurate optimal onset time in the present study.

A significant increase in the proper induction time was proven with TOF monitoring during infusion with remifentanil at 1.0 µg/kg/minute. This study revealed significant differences among the three groups. The BP and HR decreased more from baseline to T~0~ in the groups with continuous infusion of remifentanil than in the saline group. All patients enrolled in the study had an ASA physical status of I or II, implying that they would respond well to the hemodynamic changes induced by endotracheal intubation. In patients with cardiovascular problems, however, the changes in BP and HR measured in this study could have significant consequences.

Our study has one main limitation. A previous study showed that remifentanil must be administered after rocuronium to decrease the risk of adverse effects. This is because the target effect--site concentration of remifentanil has shorter latency than rocuronium.^[@bibr18-0300060518772227]^ For rapid-sequence induction, remifentanil relieves the surge of sympathetic tone after endotracheal intubation. In conclusion, continuous infusion of remifentanil increases the optimal neuromuscular blockade time for tracheal intubation.
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